RecruitingPhase 2NCT06955169

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

Studying Meningioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
RTOG Foundation, Inc.
Principal Investigator
Erik P Sulman, MD,PhD
Duke University
Intervention
[177Lu]Lu-DOTATATE(drug)
Enrollment
153 enrolled
Eligibility
18 years · All sexes
Timeline
20252030

Study locations (9)

Collaborators

Novartis Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06955169 on ClinicalTrials.gov

Other trials for Meningioma

Additional recruiting or active studies for the same condition.

See all trials for Meningioma

← Back to all trials